ASTRAZENECA PLC reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Cambridge
SEC filing record 1 source field available
Fiscal year end
31 December
ASTRAZENECA PLC has filed 2,047 SEC EDGAR filings since 13 Mar 1995

SEC filing history

Showing 976-1,000 of 1,000 matching filings.

Per page
25
Current page
40
6-K File 001-11960

LYNPARZA PHASE III PAOLA-1 TRIAL MET PRIMARY ENDPOINT

Filing date
14 Aug 2019
Reporting date
14 Aug 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TAGRISSO SIGNIFICANTLY IMPROVES OVERALL SURVIVAL

Filing date
09 Aug 2019
Reporting date
09 Aug 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA PHASE III PROFOUND TRIAL IN HRR*

Filing date
07 Aug 2019
Reporting date
07 Aug 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FORXIGA LABEL UPDATED IN THE EU IN TYPE-2 DIABETES

Filing date
05 Aug 2019
Reporting date
05 Aug 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Aug 2019
Reporting date
01 Aug 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

UPDATE ON US REGULATORY DECISION FOR FARXIGA

Filing date
15 Jul 2019
Reporting date
15 Jul 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI GRANTED US ORPHAN DRUG DESIGNATION FOR SMALL CELL LUNG CANCER

Filing date
12 Jul 2019
Reporting date
12 Jul 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FASENRA RECEIVES POSITIVE EU CHMP OPINION FOR SELF

Filing date
01 Jul 2019
Reporting date
01 Jul 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Jul 2019
Reporting date
01 Jul 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FORXIGA RECEIVES POSITIVE EU CHMP OPINION FOR

Filing date
01 Jul 2019
Reporting date
01 Jul 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
11-K File 001-11960

11-K filing

Filing date
27 Jun 2019
Reporting date
31 Dec 2018
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI IMPROVES OVERALL SURVIVAL AT INTERIM

Filing date
27 Jun 2019
Reporting date
27 Jun 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

BREZTRI AEROSPHERE (PT010) APPROVED IN JAPAN FOR PATIENTS WITH CHRONIC OBSTRUCTI

Filing date
19 Jun 2019
Reporting date
19 Jun 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA APPROVED IN JAPAN FOR 1ST-LINE MAINTENANCE THERAPY IN BRCA-MUTATED ADVA

Filing date
19 Jun 2019
Reporting date
19 Jun 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

BEVESPI AEROSPHERE APPROVED BY THE JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFA

Filing date
19 Jun 2019
Reporting date
19 Jun 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA APPROVED IN THE EU FOR 1ST-LINE

Filing date
18 Jun 2019
Reporting date
18 Jun 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

CALQUENCE SIGNIFICANTLY PROLONGED THE TIME PATIENT

Filing date
17 Jun 2019
Reporting date
17 Jun 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

PUBLICATION OF A PROSPECTUS

Filing date
12 Jun 2019
Reporting date
12 Jun 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

CALQUENCE PHASE III ELEVATE-TN TRIAL MET PRIMARY

Filing date
06 Jun 2019
Reporting date
06 Jun 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

BLOCK LISTING INTERIM REVIEW

Filing date
03 Jun 2019
Reporting date
03 Jun 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
03 Jun 2019
Reporting date
03 Jun 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA NEARLY DOUBLED THE TIME PATIENTS LIVED WITHOUT DISEASE PROGRESSION FROM

Filing date
03 Jun 2019
Reporting date
03 Jun 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

POOLED ANALYSES OF THE ROXADUSTAT GLOBAL PHASE III

Filing date
10 May 2019
Reporting date
10 May 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
08 May 2019
Reporting date
08 May 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .